MENORA MIVTACHIM HOLDINGS LTD.MENORA MIVTACHIM HOLDINGS LTD.

Institutional investor · Portfolio as of Q2 2025

SEC EDGAR SourceSEC Filings

Top Holdings131 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

MICROSOFT CORP

2.8M$1.4B8.1%$228.73+116.06%
26 qtrssince 2019-Q1
Decreased
0

NVIDIA CORP

6.4M$1B5.9%$118.82+32.75%
26 qtrssince 2019-Q1
Increased
62

APPLE INC

4.8M$981.2M5.6%$147.11+38.80%
26 qtrssince 2019-Q1
Increased
62

ALPHABET INC-CL A

4.6M$813.1M4.7%$100.51+77.35%
26 qtrssince 2019-Q1
Increased
58

AMAZON.COM INC

3.4M$744.2M4.3%$137.35+62.58%
26 qtrssince 2019-Q1
Increased
63

META PLATFORMS INC-CLASS A

951,865$702.6M4.0%$273.44+167.90%
21 qtrssince 2020-Q2
Increased
58
TEVATEVA
ADR

TEVA PHARMACEUTICAL-SP ADR

38.5M$645.1M3.7%$11.37+47.37%
23 qtrssince 2019-Q4
Increased
74

BROADCOM INC

1.7M$479.8M2.8%$217.61+23.33%
3 qtrssince 2024-Q4
Increased
66

JPMORGAN CHASE & CO

1.5M$429.7M2.5%$146.85+92.76%
8 qtrssince 2023-Q3
Unchanged
0

MASTERCARD INC - A

689,960$387.7M2.2%$341.13+60.65%
18 qtrssince 2021-Q1
Unchanged
0
FLINFLIN
ETF

FRANKLIN TEMPLETON ETF TR

9.3M$371.6M2.1%$33.47+18.99%
9 qtrssince 2023-Q2
Unchanged
0

NOVA LTD

1.3M$348.1M2.0%$49.23+443.66%
26 qtrssince 2019-Q1
Unchanged
0
XLIXLI
ETF

INDUSTRIAL SELECT SECT SPDR

2.3M$343.6M2.0%$129.81+12.23%
7 qtrssince 2023-Q4
Decreased
0

APPLIED MATERIALS INC

1.7M$310.4M1.8%$122.44+48.43%
18 qtrssince 2021-Q1
Unchanged
0
IHIIHI
ETF

ISHARES TR

4.9M$304.7M1.8%$59.25+4.54%
2 qtrssince 2025-Q1
Decreased
0
NICENICE
ADR

NICE LTD - SPON ADR

1.7M$280.4M1.6%$182.26-9.42%
6 qtrssince 2024-Q1
Unchanged
0
XLPXLP
ETF

CONSUMER STAPLES SPDR

3.3M$269.4M1.5%$76.33+3.97%
10 qtrssince 2023-Q1
Increased
48
XLUXLU
ETF

UTILITIES SELECT SECTOR SPDR

3.2M$260.3M1.5%$38.09+5.24%
10 qtrssince 2023-Q1
Increased
56
XLEXLE
ETF

ENERGY SELECT SECTOR SPDR

2.9M$249M1.4%$44.11-4.95%
10 qtrssince 2023-Q1
Decreased
0
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

1.1M$248.4M1.4%$94.09+141.51%
11 qtrssince 2022-Q4
Unchanged
0
$17.4B
AUM
131
Positions
Q2 2025
Filing
Rating · 2.0
Quarterly Portfolio Change
+12%Q1'24$13.3B+10%Q2'24$14.7B+8%Q3'24$15.9B+1%Q4'24$16B-3%Q1'25$15.4B+13%Q2'25$17.4B
Activity profile
$ moved · Q2'25
New7%Increased54%Decreased37%Exited2%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.4 years
<1Q7%1-4Q26%1-2Y13%2Y+54%

MENORA MIVTACHIM HOLDINGS LTD. manages $17.4B across 131 positions as of Q2 2025. Top holdings: MSFT (8.1%), NVDA (5.9%), AAPL (5.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.

Q2 2025 Summary

Active quarter - 11 new positions, 5 exits, 48 increased. Top move: TEVA (INCREASED, conviction 74). Portfolio: $17.4B across 131 positions.

Top holdings by portfolio weight

Total AUM$17B
MSFT8.13%
NVDA5.85%
AAPL5.64%
GOOGL4.68%
AMZN4.28%
META4.04%
TEVA3.71%
AVGO2.76%
JPM2.47%
MA2.23%
Other2.14%

Portfolio allocation by GICS sector

Sectors11
Technology34.18%
Unknown21.97%
Financial Services9.68%
Communication Services8.80%
Healthcare8.33%
Consumer Cyclical8.07%
Consumer Defensive3.56%
Industrials2.57%
Real Estate1.07%
Basic Materials1.04%
Other0.74%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Technology, Unknown
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record52
Conviction45
Concentration62
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
6Q
TEVATEVATEVA PHARMACEUTICAL-SP ADR
Q1 2025 Q2 2026+11.5M shares+$724.7M
5Q
KREKRESPDR SERIES TRUST
Q2 2025 Q2 2026+3.3M shares+$248M
4Q
QQQQQQINVESCO QQQ TRUST SERIES 1 CL USD INC
Q3 2025 Q2 2026+10,060 shares+$9.7M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used